5150 related articles for article (PubMed ID: 3860479)
21. Autologous cellular immune response to primary and metastatic human melanomas and its regulation by DR antigens expressed on tumor cells.
Parmiani G; Fossati G; Taramelli D; Anichini A; Balsari A; Gambacorti-Passerini C; Sciorelli G; Cascinelli N
Cancer Metastasis Rev; 1985; 4(1):7-26. PubMed ID: 3888384
[TBL] [Abstract][Full Text] [Related]
22. Major histocompatibility antigens and mononuclear inflammatory infiltrate in benign nevomelanocytic proliferations and malignant melanoma.
Ruiter DJ; Bhan AK; Harrist TJ; Sober AJ; Mihm MC
J Immunol; 1982 Dec; 129(6):2808-15. PubMed ID: 6183345
[TBL] [Abstract][Full Text] [Related]
23. Phenotypic heterogeneity of HLA products on human melanoma cells.
Parmiani G; Taramelli D; Anichini A; Andreola S; Cascinelli N; Fossati G
J Immunogenet; 1986; 13(2-3):235-40. PubMed ID: 3469277
[TBL] [Abstract][Full Text] [Related]
24. HLA-DR antigen expression in primary melanomas of the skin.
Bröcker EB; Suter L; Sorg C
J Invest Dermatol; 1984 Mar; 82(3):244-7. PubMed ID: 6366074
[TBL] [Abstract][Full Text] [Related]
25. Differential expression of melanoma associated antigens in acral lentiginous melanoma and in nodular melanoma lesions.
Kageshita T; Nakamura T; Yamada M; Kuriya N; Arao T; Ferrone S
Cancer Res; 1991 Mar; 51(6):1726-32. PubMed ID: 1671829
[TBL] [Abstract][Full Text] [Related]
26. Antigenic profiles of individual-matched pairs of primary and melanoma metastases.
Meije CB; Swart GW; Lepoole C; Das PK; Van den Oord JJ
Hum Pathol; 2009 Oct; 40(10):1399-407. PubMed ID: 19386352
[TBL] [Abstract][Full Text] [Related]
27. Recombinant gamma-interferon induces changes in expression and shedding of antigens associated with normal human melanocytes, nevus cells, and primary and metastatic melanoma cells.
Herlyn M; Guerry D; Koprowski H
J Immunol; 1985 Jun; 134(6):4226-30. PubMed ID: 2985706
[TBL] [Abstract][Full Text] [Related]
28. Monoclonal antibodies to human melanoma associated antigens: study of their specificity and visualization at the cellular level of the antigenic distribution.
Libert A; Ghanem G; Arnould R; Vercammen-Grandjean A; Carrel S; Lejeune F
Anticancer Res; 1983; 3(4):219-25. PubMed ID: 6576727
[TBL] [Abstract][Full Text] [Related]
29. Antigenic heterogeneity of skin tumors of nonmelanocyte origin: analysis with monoclonal antibodies to tumor-associated antigens and to histocompatibility antigens.
Natali PG; Viora M; Nicotra MR; Giacomini P; Bigotti A; Ferrone S
J Natl Cancer Inst; 1983 Sep; 71(3):439-47. PubMed ID: 6577218
[TBL] [Abstract][Full Text] [Related]
30. Modulation by recombinant DNA leukocyte (alpha) and fibroblast (beta) interferons of the expression and shedding of HLA- and tumor-associated antigens by human melanoma cells.
Giacomini P; Aguzzi A; Pestka S; Fisher PB; Ferrone S
J Immunol; 1984 Sep; 133(3):1649-55. PubMed ID: 6747299
[TBL] [Abstract][Full Text] [Related]
31. Melan-A/MART-1 antigen expression in cutaneous and ocular melanomas.
Nicotra MR; Nisticò P; Mangoni A; Di Filippo F; Marincola FM; Natali PG
J Immunother; 1997 Nov; 20(6):466-9. PubMed ID: 9409452
[TBL] [Abstract][Full Text] [Related]
32. Phenotypic and genetic analysis of HLA class I and HLA-DR antigen expression on human melanomas.
López-Nevot MA; Garcia E; Romero C; Oliva MR; Serrano S; Garrido F
Exp Clin Immunogenet; 1988; 5(4):203-12. PubMed ID: 3078572
[TBL] [Abstract][Full Text] [Related]
33. HLA-DR and 96-K antigens and intratumoral lymphocytic infiltrate in primary cutaneous melanoma as markers of tumor progression.
Brogelli L; Moretti S; Borgognoni L; Giannotti B
Dermatologica; 1990; 180(2):69-72. PubMed ID: 2311798
[TBL] [Abstract][Full Text] [Related]
34. MHC antigens in human melanomas.
Ruiter DJ; Mattijssen V; Broecker EB; Ferrone S
Semin Cancer Biol; 1991 Feb; 2(1):35-45. PubMed ID: 1912517
[TBL] [Abstract][Full Text] [Related]
35. Level of HLA antigens in locoregional metastases and clinical course of the disease in patients with melanoma.
van Duinen SG; Ruiter DJ; Broecker EB; van der Velde EA; Sorg C; Welvaart K; Ferrone S
Cancer Res; 1988 Feb; 48(4):1019-25. PubMed ID: 3338074
[TBL] [Abstract][Full Text] [Related]
36. The differential reactivity of benign and malignant nevomelanocytic lesions with mouse monoclonal antibody TNKH1.
Nakanishi T; Hashimoto K
Cancer; 1987 Apr; 59(7):1340-4. PubMed ID: 3545436
[TBL] [Abstract][Full Text] [Related]
37. Human monoclonal antibodies that distinguish cutaneous malignant melanomas from benign nevi in fixed tissue sections.
Imam A; Mitchell MS; Modlin RL; Taylor CR; Kempf RA; Kan-Mitchell J
J Invest Dermatol; 1986 Feb; 86(2):145-8. PubMed ID: 3528308
[TBL] [Abstract][Full Text] [Related]
38. Antigenic profile of human melanoma cells. Analysis with monoclonal antibodies to histocompatibility antigens and to melanoma-associated antigens.
Natali PG; Giacomini P; Russo C; Steinbach G; Fenoglio C; Ferrone S
J Cutan Pathol; 1983 Aug; 10(4):225-37. PubMed ID: 6350388
[No Abstract] [Full Text] [Related]
39. Surface antigens of melanomas and melanocytes defined by mouse monoclonal antibodies: specificity analysis and comparison of antigen expression in cultured cells and tissues.
Real FX; Houghton AN; Albino AP; Cordon-Cardo C; Melamed MR; Oettgen HF; Old LJ
Cancer Res; 1985 Sep; 45(9):4401-11. PubMed ID: 4028024
[TBL] [Abstract][Full Text] [Related]
40. HLA expression in a primary uveal melanoma, its cell line, and four of its metastases.
Blom DJ; Schurmans LR; De Waard-Siebinga I; De Wolff-Rouendaal D; Keunen JE; Jager MJ
Br J Ophthalmol; 1997 Nov; 81(11):989-93. PubMed ID: 9505825
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
